NASDAQ:VTVT vTv Therapeutics (VTVT) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free VTVT Stock Alerts $23.53 -0.27 (-1.13%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$22.81▼$25.0750-Day Range$7.87▼$29.0052-Week Range$7.38▼$39.60Volume15,144 shsAverage Volume43,145 shsMarket Capitalization$70.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get vTv Therapeutics alerts: Email Address Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About vTv Therapeutics Stock (NASDAQ:VTVT)vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.Read More VTVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VTVT Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comvTv Therapeutics Inc. (NASDAQ:VTVT) Sees Large Growth in Short InterestMarch 22, 2024 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above 50-Day Moving Average of $12.00March 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 19, 2024 | finance.yahoo.comCANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITMarch 13, 2024 | finanznachrichten.devTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateMarch 13, 2024 | globenewswire.comvTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateMarch 6, 2024 | investing.comvTv Therapeutics starts phase 3 trial for diabetes drugMarch 4, 2024 | investorplace.comThe Top 3 Healthcare Stocks to Buy on Weakness in 2024March 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 4, 2024 | globenewswire.comvTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 DiabetesMarch 1, 2024 | globenewswire.comvTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare ConferenceFebruary 29, 2024 | bizjournals.comvTv Therapeutics' stock doubles after raising $51 million from health care investors including JDRFFebruary 28, 2024 | msn.comWhy Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today?February 28, 2024 | finance.yahoo.comvTv Therapeutics Inc. (VTVT)February 28, 2024 | markets.businessinsider.comNasdaq Down 50 Points; US Crude Stocks Rise By 4.2M BarrelsFebruary 28, 2024 | marketwatch.comVTv Therapeutics Shares Surge on $51 Million Private PlacementFebruary 28, 2024 | wsj.comvTv Therapeutics Inc. Cl AFebruary 28, 2024 | finance.yahoo.comvTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundFebruary 28, 2024 | globenewswire.comvTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundFebruary 22, 2024 | prnewswire.comCANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCEJanuary 31, 2024 | uk.investing.comvTv Therapeutics Inc (VTVT)November 27, 2023 | money.usnews.comvTv Therapeutics Inc - Ordinary Shares - Class ANovember 21, 2023 | bizjournals.comvTv Therapeutics regains compliance with Nasdaq after 1-for-40 reverse stock splitNovember 15, 2023 | bizjournals.comvTv Therapeutics loses $6.7M in Q3, could lose spot on NASDAQ indexNovember 11, 2023 | benzinga.comvTv Therapeutics Stock (NASDAQ:VTVT) Earnings Dates and Earning CallsNovember 10, 2023 | finanznachrichten.devTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate UpdateNovember 9, 2023 | finance.yahoo.comvTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate UpdateSee More Headlines Receive VTVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2023Today3/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VTVT CUSIPN/A CIK1641489 Webwww.vtvtherapeutics.com Phone(336) 841-0300Fax336-841-0310Employees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($10.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,250,000.00 Net MarginsN/A Pretax Margin-306,833.34% Return on EquityN/A Return on Assets-104.93% Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio1.00 Sales & Book Value Annual Sales$2.02 million Price / Sales35.06 Cash FlowN/A Price / Cash FlowN/A Book Value($9.27) per share Price / Book-2.54Miscellaneous Outstanding Shares3,010,000Free Float2,959,000Market Cap$70.83 million OptionableNot Optionable Beta0.51 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Paul J. Sekhri M.Sc. (Age 66)CEO, President & Director Comp: $483.43kMr. Steven Tuch M.B.A. (Age 55)Executive VP & CFO Comp: $449.16kMr. Barry Brown (Age 63)Chief Accounting Officer Comp: $311.98kMr. Richard S. Nelson (Age 53)Executive VP of Corporate Development & Director Comp: $201.08kDr. Carmen Valcarce Ph.D.Chief Scientific Officer & Executive VPVanessa McDadeChief Administrative OfficerMs. Elizabeth M. Keiley (Age 58)Executive VP & General Counsel Dr. Thomas Strack M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsImmuneeringNASDAQ:IMRXJourney MedicalNASDAQ:DERMKronos BioNASDAQ:KRONAssembly BiosciencesNASDAQ:ASMBLandos BiopharmaNASDAQ:LABPView All CompetitorsInstitutional OwnershipVanguard Group Inc.Sold 916,104 shares on 3/11/2024Ownership: 0.901%Vanguard Group Inc.Sold 916,104 shares on 2/15/2024Ownership: 0.901%View All Institutional Transactions VTVT Stock Analysis - Frequently Asked Questions How have VTVT shares performed in 2024? vTv Therapeutics' stock was trading at $11.50 at the beginning of 2024. Since then, VTVT shares have increased by 104.6% and is now trading at $23.53. View the best growth stocks for 2024 here. Are investors shorting vTv Therapeutics? vTv Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 57,200 shares, an increase of 50.5% from the February 29th total of 38,000 shares. Based on an average daily trading volume, of 75,100 shares, the days-to-cover ratio is presently 0.8 days. Currently, 10.9% of the company's shares are short sold. View vTv Therapeutics' Short Interest. When is vTv Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VTVT earnings forecast. How were vTv Therapeutics' earnings last quarter? vTv Therapeutics Inc. (NASDAQ:VTVT) posted its earnings results on Monday, March, 6th. The biotechnology company reported ($2.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($2.40). The biotechnology company had revenue of $0.01 million for the quarter. When did vTv Therapeutics' stock split? vTv Therapeutics shares reverse split on the morning of Tuesday, November 21st 2023. The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of vTv Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA). When did vTv Therapeutics IPO? vTv Therapeutics (VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers. Who are vTv Therapeutics' major shareholders? vTv Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.90%) and Vanguard Group Inc. (0.90%). Insiders that own company stock include John A Fry and Ronald O Perelman. View institutional ownership trends. How do I buy shares of vTv Therapeutics? Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VTVT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.